Opinion
Video
Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring